Earnings summaries and quarterly performance for Bioventus.
Executive leadership at Bioventus.
Board of directors at Bioventus.
GJ
Guido J. Neels
Detailed
Director
GP
Guy P. Nohra
Detailed
Director
JA
John A. Bartholdson
Detailed
Director
MP
Martin P. Sutter
Detailed
Director
MK
Mary Kay Ladone
Detailed
Director
MM
Michelle McMurry-Heath
Detailed
Director
PJ
Patrick J. Beyer
Detailed
Director
PG
Philip G. Cowdy
Detailed
Director
SM
Susan M. Stalnecker
Detailed
Director
WA
William A. Hawkins
Detailed
Chairperson
Research analysts who have asked questions during Bioventus earnings calls.
CC
Caitlin Cronin
Canaccord Genuity
4 questions for BVS
Also covers: ATEC, AXGN, ENOV +10 more
Chase Knickerbocker
Craig-Hallum Capital Group
4 questions for BVS
Also covers: AVDL, BFLY, CELC +17 more
RM
Robert Marcus
JPMorgan Chase & Co.
3 questions for BVS
Also covers: ABT, BAX, BDX +21 more
LL
Lilia-Celine Lozada
JPMorgan Chase & Co.
1 question for BVS
Also covers: ATRC, CBLL, IART +4 more
MP
Matthew Park
Cantor Fitzgerald
1 question for BVS
Also covers: AXGN, CERS, ORGO +5 more
Recent press releases and 8-K filings for BVS.
Bioventus Highlights Strong Performance and Future Growth Drivers at J.P. Morgan Healthcare Conference
BVS
Revenue Acceleration/Inflection
New Projects/Investments
Product Launch
- Bioventus has undergone a significant transformation, achieving revenue growth well above the market, sustaining peer-leading gross margins in the mid-70s%, expanding EBITDA margins by roughly 700 basis points, and delivering over $100 million in operating cash flow in the last two years.
- The company is focused on igniting four growth drivers: peripheral nerve stimulation (PNS), platelet-rich plasma (PRP), ultrasonics, and international expansion, with PNS and PRP alone expected to contribute 200 basis points of growth in 2026.
- Bioventus expects adjusted EPS for 2026 to grow two to three times faster than revenue and anticipates 2025 cash flow to nearly double from the prior year, with further acceleration expected in 2026 due to reduced debt and increased operating profit.
- The primary capital allocation priority is to continue paying down debt, aiming to reduce the leverage ratio below two times, having already lowered debt to below $300 million and the leverage ratio to below two and a half times.
6 days ago
Bioventus Highlights Transformation, Growth Drivers, and Financial Strength at J.P. Morgan Healthcare Conference
BVS
New Projects/Investments
Revenue Acceleration/Inflection
Guidance Update
- Bioventus, generating over $550 million in annual revenue, has undergone a transformation, focusing on three businesses: pain treatments, surgical solutions, and restorative therapies.
- The company is igniting four powerful growth drivers: Peripheral Nerve Stimulation (PNS), Platelet-Rich Plasma (PRP), Ultrasonics, and International expansion, with a goal to become a $1 billion med tech company.
- Bioventus has achieved a peer-leading gross margin in the mid-70s%, expanded EBITDA margins by approximately 700 basis points, and delivered over $100 million in operating cash flow in the last two years.
- The company has significantly reduced its debt to below $300 million, lowering its leverage ratio to below 2.5 times, and expects adjusted EPS for 2026 to grow two to three times faster than revenue.
- Cash flow nearly doubled in 2025 compared to the prior year, with further acceleration anticipated in 2026 due to lower interest expenses and increased operating profit.
6 days ago
Bioventus Highlights Transformation, Growth Drivers, and Financial Strength at J.P. Morgan Healthcare Conference
BVS
Revenue Acceleration/Inflection
New Projects/Investments
Guidance Update
- Bioventus has undergone a significant transformation, achieving revenue growth well above the market, sustaining a peer-leading gross margin in the mid-70s%, expanding EBITDA margins by roughly 700 basis points, and generating over $100 million in operating cash flow in the last two years.
- The company has significantly reduced its leverage ratio by more than half, with debt now below $300 million and a leverage ratio below 2.5 times. The top capital allocation priority is further debt reduction, with a clear line of sight to reducing it below 2 times.
- Bioventus is focused on igniting four growth drivers: Ultrasonics, International, Peripheral Nerve Stimulation (PNS), and Platelet-Rich Plasma (PRP). PNS and PRP are expected to contribute 200 basis points of growth to Bioventus in 2026.
- For 2026, adjusted EPS is expected to grow two to three times faster than revenue, and cash flow is anticipated to accelerate further, building on the nearly doubled cash flow from 2025. The company is planning for $1-$2 million in tariffs in 2026.
6 days ago
Bioventus outlines accelerated growth and profitability targets at J.P. Morgan Healthcare Conference
BVS
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- Bioventus projects significant acceleration in organic revenue growth from 1% in 2022 to an estimated ~7% in 2025 and 10%+ in the future, with Adjusted EBITDA margin expected to increase from 13% in 2022 to ~20% in 2025 and ~25% in the future.
- The company's strategy focuses on advancing its portfolio with new growth drivers such as Peripheral Nerve Stimulation (PNS) and Platelet-Rich Plasma (PRP), divesting non-core assets, and enhancing commercial execution.
- In 2025, Bioventus generated cash flow almost double that of 2024, reducing debt to below $300 million and net leverage to below 2.5x.
- For 2026, the company plans to invest in growth drivers and anticipates EPS growth to be 2-3 times its revenue growth.
6 days ago
BioStem Technologies Launches New American Amnion Product Line
BVS
Product Launch
New Projects/Investments
- BioStem Technologies, Inc. (OTC: BSEM) launched its new American Amnion product line at the Desert Foot Multi-Disciplinary Limb Salvage and Wound Care Conference on December 10-13, 2025.
- The new line, comprising American Amnion and American Amnion AC, consists of placental-derived allografts for advanced wound care, produced using the company's proprietary BioRetain® technology.
- Clinical studies have demonstrated the products' efficacy, with one study showing a 53% wound closure probability versus 31% for standard of care, and another demonstrating a 14% reduction in time to closure and 27% fewer applications compared to a competitor.
- The launch aims to address the needs of the underserved veteran population with chronic wounds, aligning with a 50% increase in placental-based product use within the VA system over the past five years.
Dec 10, 2025, 12:00 PM
Bioventus CEO highlights growth strategy and financial improvements
BVS
Revenue Acceleration/Inflection
New Projects/Investments
Guidance Update
- Bioventus (BVS) aims to become a $1 billion high-growth, high-profit, high-cash flow company, currently generating over $550 million in annual revenue across Pain Treatments, Surgical Solutions, and Restorative Therapies.
- The company anticipates growing nearly 2X the weighted average market growth rate this year, supported by a peer-leading gross margin in the mid-70s and an EBITDA margin guidance of just over 20%.
- Significant financial improvements are expected, with cash flow projected to nearly double this year and net leverage anticipated to drop below 2.5x by year-end.
- Growth is driven by core, expansion, and emerging categories, with emerging growth drivers like PNS and PRP expected to contribute at least 200 basis points of growth next year, following the recent FDA 510(k) clearance for StimTrial.
Dec 3, 2025, 3:10 PM
Bioventus Presents Investment Opportunity and Financial Performance at 2025 Piper Sandler Healthcare Conference
BVS
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- Bioventus highlighted a $6.4 billion market opportunity and reported $564 million in LTM Global Proforma Revenue as of September 27, 2025.
- The company projects significant financial improvement for 2025, with 7.0% organic growth and an Adjusted EBITDA Margin of 20.2%, based on the midpoint of guidance provided on March 11, 2025.
- Bioventus aims to accelerate cash flow and reduce leverage, with Cash from Operations projected to reach $66.1 million in 2025 and the Net Leverage Ratio expected to be below 2.5x by the end of 2025.
- The company maintains a peer-leading, consistent mid-70s gross margin, which supports re-investment in growth opportunities and EBITDA margin expansion.
Dec 3, 2025, 3:10 PM
Bioventus CEO Highlights Strong Growth Trajectory and Financial Improvements
BVS
Revenue Acceleration/Inflection
New Projects/Investments
Guidance Update
- Bioventus, led by CEO Rob Claypoole, generates over $550 million in annual revenue and operates in a $6 billion market opportunity across pain treatment, surgical solutions, and restorative therapies.
- The company has demonstrated above-market growth for the past eight quarters and expects to grow nearly 2X the weighted average market growth rate this year, aiming to become a $1 billion high-growth, high-profit, high-cash flow company.
- Bioventus projects significant financial improvements, including a peer-leading gross margin in the mid-70s, an EBITDA margin guidance of just over 20% for this year (a 100 basis points improvement), and cash flow expected to nearly double this year.
- The company is focused on three growth driver categories: Core (HA, BGS, fracture care), Expansion (Ultrasonics, International), and Emerging (PNS, PRP), with emerging drivers like PNS and PRP expected to generate at least 200 basis points of growth next year.
- Leverage is expected to drop below 2.5x by the end of this year, providing greater optionality for capital deployment.
Dec 3, 2025, 3:10 PM
Bioventus Announces Q3 2025 Results and Reaffirms Full-Year Guidance
BVS
Earnings
Guidance Update
Product Launch
- Bioventus reported Q3 2025 revenue of $139 million, comparable to the prior year due to a divestiture, with 8% organic growth.
- The company achieved a GAAP net income of $3 million in Q3 2025, an improvement from a net loss of $5 million in the prior year, and Adjusted EBITDA increased by 13% to $27 million.
- Bioventus reaffirmed its full-year 2025 financial guidance, expecting net sales between $560 million and $570 million and Adjusted EBITDA between $112 million and $116 million.
- Pilot launches for Peripheral Nerve Stimulation (PNS) and Platelet-Rich Plasma (PRP) are progressing well and are anticipated to provide at least 200 basis points of profitable growth in 2026.
Nov 4, 2025, 1:30 PM
Bioventus Reports Strong Q3 2025 Results and Reaffirms Full-Year Guidance
BVS
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Bioventus reported Q3 2025 revenue of $139 million, achieving 8% organic growth, and adjusted EBITDA increased by 13% to $27 million, expanding the adjusted EBITDA margin by 220 basis points.
- Adjusted earnings per diluted share for Q3 2025 increased by 200% to $0.15.
- The company generated $30 million in cash flow from operations in Q3 2025, an increase of $20 million compared to the prior year, and reduced debt by $19 million, bringing the net leverage ratio below three times.
- Bioventus reaffirmed its 2025 financial guidance, including organic revenue growth of 6%-8%, adjusted EBITDA of $112 million-$116 million, and EPS of $0.64-$0.68.
- Strategic initiatives like the limited launch of StimTrial and Talisman (PNS) are tracking ahead of expectations, and the new PRP system, Excel, is receiving positive feedback, with both expected to contribute at least 200 basis points of profitable growth in 2026.
Nov 4, 2025, 1:30 PM
Quarterly earnings call transcripts for Bioventus.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more